5Q Spectra to Debut Blood Test for Prostate Cancer Detection
5Q Spectra plans to launch the Prostate Dx blood test, designed to help assess prostate cancer risk after elevated PSA results and potentially reduce unnecessary biopsies.
Category: Prostate
Prostate
Latest
Prostate
Latest
Myriad Genetics Launches Prostate Cancer Test Combining Genomics and AI
The test combines genomic risk assessment and digital pathology analysis to help clinicians tailor monitoring strategies.
Prostate
Latest
EpiCapture Urine-Based Prostate Cancer Test Shows High Accuracy in Clinical Study
The updated urine test utilizes machine learning and patient ethnicity to provide individualized risk scores for aggressive disease.
PSA Screening Shows Sustained Prostate Cancer Mortality Reduction in 23-Year Study
Research demonstrates 13% relative reduction in prostate cancer deaths but highlights overdiagnosis concerns, prompting calls for risk-based screening approaches.
Read More
Prostate-specific Antigen Testing in England Shows Concerning Patterns of Overuse
A study of over 10 million men reveals frequent testing of patients unlikely to benefit, raising questions about current screening practices.
Read More
Genetic Test Now Available to Predict Radiation Therapy Side Effects in Prostate Cancer
PROSTOX ultra identifies patients at higher risk of developing late genitourinary toxicity from stereotactic body radiation therapy.
Read More
Prospective Trial Shows PAM50 Biomarker Predicts Hormone Therapy Benefit in Prostate Cancer
Study finds molecular signature identifies which men with recurrent disease respond to apalutamide plus salvage radiation therapy.
Read More
Genomic Test Shows Promise for Guiding Chemotherapy Decisions in Metastatic Prostate Cancer
Phase 3 STAMPEDE trial data demonstrates Decipher Prostate test can predict docetaxel treatment benefit, potentially helping patients avoid unnecessary toxicity.
Read More
FDA Grants De Novo Authorization for AI-Powered Prostate Cancer Prognostic Software
The risk stratification tool is designed to predict long-term outcomes for patients with non-metastatic prostate cancer.
Read More
Prostate Cancer Biomarkers and PVSA Research Presented
Fellow Health showcased innovative research, emphasizing mail-in semen testing to enhance prostate cancer diagnostics and PVSA care.
Read More
Veracyte Expands Availability of Decipher Prostate TestÂ
Veracyte has launched Decipher Prostate test, a Medicare-covered test for guiding treatment in metastatic prostate cancer.
Read More
Landmark Longitudinal Prostate Cancer Study Released
A new study confirms Cleveland Diagnostics’ IsoPSA test effectively differentiates between low- and high-risk prostate cancer patients.
Read More
Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in SEER Specialized Database Release
Decipher Prostate Genomic Classifier data is included in a new SEER Program database, enabling the study of prostate cancer outcomes.
Read More
Lynx Dx Launches At-Home Prostate Cancer Test
Lynx Dx announced at-home availability of a urine-based prostate cancer test that eliminates the need for a digital rectal exam.
Read More
Urine Test Detects Prostate Cancer and Reduces Unnecessary Biopsies
A new study validated a urine test that offers a less invasive, more accurate alternative to traditional prostate cancer screening.
Read More
Why Genomic Tests for Prostate Cancer Need Better Data
A review found gaps remain for genomic classifier tests for their cost-effectiveness, clinical utility, and impact on diverse populations.
Read More
New Blood Test Predicts Prognosis for Advanced Prostate Cancer Patients
The AR-ctDETECT test identifies circulating tumor DNA in advanced prostate cancer patients, providing critical insights for prognostication.
Read More
Researchers Discover Genetic Marker to Identify Aggressive Prostate Cancers Early
A genetic variant in the PSA gene may help improve prostate cancer diagnostics by distinguishing between aggressive and non-aggressive types.
Read More